With the addition of Ganirelix, Ferring continues to offer the most complete reproductive medicine portfolio available, which includes Menopur (menotropins for injection), NOVAREL (chorionic gonadotropin for injection, USP) and Endometrin (progesterone) Vaginal Insert.
Ganirelix is a GnRH antagonist used to prevent premature luteinizing hormone surges in women undergoing fertility treatment.
On November 30, 2018, Sun Pharma received final approval from the US FDA for its Abbreviated New Drug Application for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL.
In addition, Ferring also finalized the transaction with INVO Bioscience Inc. to acquire the exclusive US commercialization rights for the INVOcell Intravaginal Culture System, which comprises the INVOcell Culture Device and Retention Device.
The INVOcell Culture Device uses a woman's own body as an incubator during fertilization and early embryo development.
In 2015, INVO Bioscience received FDA clearance for the INVOcell IVC system, making it the first IVC system marketed in the US.
Through this acquisition, Ferring will use its resources and expertise in the field of assisted reproductive technologies to help reproductive endocrinology practices across the country expand their service offerings to include the IVC procedure, in addition to their current treatment offerings of intrauterine insemination and in vitro fertilization.
In the US, statistics show that over 1.4m women may benefit from advanced fertility treatment. However, only approximately 130,000 people begin such treatment.2
Ferring Pharmaceuticals is a biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, women's health, urology, gastroenterology, endocrinology and orthopaedics.
Ganirelix Acetate Injection is used to prevent premature ovulation during controlled ovarian stimulation.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical